Law360, New York (September 14, 2012, 2:49 PM ET) -- Avanir Pharmaceuticals Inc. sued a handful of other drug companies in Delaware federal court on Wednesday, alleging their plans to make a generic treatment for a condition associated with neurological disorders infringe a patent covering its branded drug Nuedexta.
In separate complaints, Avanir said that abbreviated new drug applications filed with the U.S. Food and Drug Administration by four generic-drug makers — Watson Pharmaceuticals Inc., Par Pharmaceutical Cos. Inc., Actavis Inc. and Wockhardt Ltd. — infringe U.S. Patent 8,227,484, which covers a drug Avanir sells as...
Avanir Sues Rivals Over Plans For Generic Neurological Drug
To view the full article, take a free trial now.
